SCHEMBL803069

SCHEMBL803069

Cc1ccc2c(c1)CCc1cc(O)ccc1-2

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MIF P14174 4/20 0.54
MAOB P27338 4/20 0.48
MAOA P21397 3/20 0.48
PRKCI P41743 1/20 0.48
ESR2 Q92731 2/20 0.47
ESR1 P03372 1/20 0.47
HSP90AA1 P07900 1/20 0.47
PARP10 Q53GL7 1/20 0.46
PARP11 Q9NR21 1/20 0.46
HSD17B1 P14061 2/20 0.44
CYP26A1 O43174 1/20 0.44
SRD5A1 P18405 1/20 0.42
AKR1B1 P15121 1/20 0.42
PBRM1 Q86U86 1/20 0.42
ACHE P22303 2/20 0.42
NR1H2 P55055 2/20 0.42
NR1H3 Q13133 2/20 0.42
PTGS1 P23219 1/20 0.42
PTGS2 P35354 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15869784 0.88 HSD17B1 (0.58) MIFMAOBMAOAESR2ESR1
SCHEMBL19422232 0.87 PARP10 (0.55) MIFMAOBMAOAPARP10PARP11
SCHEMBL784291 0.87 MAOB (0.59) MIFMAOBMAOAPRKCIESR2
SCHEMBL10122888 0.86 MIF (0.54) MIFMAOBMAOAPRKCIESR2
SCHEMBL26767879 0.82 ESR1 (0.44) MIFMAOBMAOAPRKCIESR2
SCHEMBL26767709 0.82 ESR2 (0.44) MIFMAOBMAOAPRKCIESR2
SCHEMBL26767884 0.81 DRD1 (0.43) MIFMAOBMAOAESR2ESR1
SCHEMBL8771857 0.80 HSD17B1 (0.54) MIFMAOBMAOAESR2ESR1
SCHEMBL26767713 0.80 HSD17B1 (0.42) MIFMAOBMAOAPRKCIESR2
SCHEMBL26767779 0.79 MAOB (0.55) MIFMAOBMAOAPRKCIESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820751-B2 Urolithin derivatives and methods of use thereof VANDRIA SA (CH) 2023-11-21 US disclosed
US-9096795-B2 Liquid crystal display MERCK PATENT GMBH (DE) 2015-08-04 US disclosed
US-20120069289-A1 LIQUID CRYSTAL DISPLAY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-03-22 US disclosed
US-20120069289-A1 LIQUID CRYSTAL DISPLAY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11820751-B2 Urolithin derivatives and methods of use thereof NLN, UQCRC2, TUFM MIF 4270/4885MAOB 590/4885MAOA 699/4885
US-20120069289-A1 LIQUID CRYSTAL DISPLAY LPXN, VCL, ACP3 MIF 3340/4885MAOB 2889/4885MAOA 2468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.